Patents Examined by Timothy P Thomas
-
Patent number: 11975121Abstract: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.Type: GrantFiled: October 28, 2020Date of Patent: May 7, 2024Assignee: PETVIVO HOLDINGS, INC.Inventors: David B. Masters, Eric P. Berg
-
Patent number: 11944621Abstract: Described is an aqueous liquid oral gliptin composition comprising a gliptin or a pharmaceutically acceptable salt or ester thereof, and an artificial non-sugar alcohol sweetening agent, the solution having a sugar alcohol content of less than 25 w/v %. The composition has an improved taste and stability as compared to known compositions. Also described is a method comprising the steps of heating 80-95 v/v % of the water to 40-65° C., admixing the antioxidant, and, if present, the chelating agent and buffering agent, optionally, cooling down to 25-35° C.Type: GrantFiled: October 23, 2020Date of Patent: April 2, 2024Assignee: AUTHENDA PHARMACEUTICALS AGInventors: Ioannis Psarrakis, Konstantinos Lioumis
-
Patent number: 11938114Abstract: Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.Type: GrantFiled: March 9, 2018Date of Patent: March 26, 2024Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Edmond J. LaVoie, Ajit Parhi, Yongzheng Zhang
-
Patent number: 11931337Abstract: Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a centration of 2-30 g/L and vitamin C having a concentration of 1-14.3 g/L. The antioxidant complex provided in the present invention can effectively reduce the number of somatic cells in a diary cow and improve milk quality.Type: GrantFiled: October 23, 2020Date of Patent: March 19, 2024Assignee: CHINA AGRICULTURAL UNIVERSITYInventor: Guoshi Liu
-
Patent number: 11925632Abstract: The present invention relates to new agents useful for the prevention and/or treatment of GLUT1-DS and related methods using the same.Type: GrantFiled: December 29, 2020Date of Patent: March 12, 2024Assignee: GLIAPHARM SAInventors: Pierre Magistretti, Sylvain Lengacher, Charles Finsterwald, Timothy John Ritchie
-
Patent number: 11919836Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.Type: GrantFiled: April 14, 2020Date of Patent: March 5, 2024Assignee: Praxis Bioresearch, LLCInventors: Sandeep Patil, Ron Bihovsky, Steven A Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
-
Patent number: 11911351Abstract: In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.Type: GrantFiled: January 30, 2019Date of Patent: February 27, 2024Assignee: APNIMED, INC. (DELAWARE)Inventors: Lawrence G. Miller, Barry Wohl, Walter J. Lunsmann
-
Patent number: 11911473Abstract: Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.Type: GrantFiled: March 30, 2023Date of Patent: February 27, 2024Assignee: AZURITY PHARMACEUTICALS, INC.Inventors: Zeus Pendon, Steven Dinh
-
Patent number: 11879831Abstract: A method of measuring a wet friction of a bundle of hair, using a system which includes a friction probe having a contact surface and fitted with a weight in the range of from 10 g to 500 g, inclusive, a means for securing the bundle of hair, and a water bath, the friction probe being connected to a texture analyser, the method including the step of i) providing a bundle of hair fibres. The method also includes the steps of ii) aligning the bundle of hair fibres; iii) securing the bundle of hair fibres; iv) immersing the bundle of hair fibres under water in the water bath; v) contacting the bundle of hair fibres with the contact surface of the friction probe, which is fitted with the weight; vi) moving the probe along the hair fibres; and vii) recording the friction generated under step vi).Type: GrantFiled: March 21, 2018Date of Patent: January 23, 2024Assignee: Conopco, Inc.Inventors: Andrew Anthony Howard Barnes, Fraser Ian Bell, Colin Christopher David Giles, Sophia Paraskevi Clare Moghadam, Rongrong Zhou
-
Patent number: 11857555Abstract: Aqueous hydrocortisone sodium phosphate and monothioglycerol formulations are disclosed.Type: GrantFiled: November 18, 2022Date of Patent: January 2, 2024Assignee: ANTARES PHARMA, INC.Inventors: Xiaoming Chen, Shaowei Ong
-
Patent number: 11786512Abstract: The present invention relates to stable pharmaceutical compositions of dihydroergotamine mesylate or other pharmaceutically acceptable salts thereof and methods for preparing the compositions particularly for the treatment of migraine headaches. The invention further relates to stable injectable composition comprising dihydroergotamine or its pharmaceutically acceptable salts thereof, wherein the composition has a pH from about 5.0 to about 6.0. Further, the present invention relates to a method of treating migraine comprising providing a stable pharmaceutical composition for parenteral administration comprising dihydroergotamine mesylate, wherein the pH of the composition ranges from 5.0 to 6.0 and, wherein the composition comprises no greater than 3% of total impurities as determined by HPLC.Type: GrantFiled: September 22, 2020Date of Patent: October 17, 2023Assignee: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Jagdish Lotan Lohar
-
Patent number: 11771662Abstract: Provided herein are treatments for reducing pain in dogs. The treatments generally comprise a combination of an opioid compound, such as methadone, and an azole compound, such as fluconazole. The treatments may further comprise an opioid abuse deterrent that advantageously inhibits opioid effects in humans while maintaining desirable analgesic effects in dogs. Additionally, the treatments provided herein avoid the undesirable side effects of prior art opioid treatments for dogs. The treatments may be administered as separate doses or in a single formulation product for improved compliance. The treatments have wide use potential in dogs from perioperative patients to inpatients and outpatients and may be used, for example, for sedation in minor procedures, analgesia, and decreasing temperature in canine patients.Type: GrantFiled: September 5, 2018Date of Patent: October 3, 2023Assignee: Kansas State University Research FoundationInventors: Stanley KuKanich, Katherine KuKanich, Charles W. Locuson, David Rankin
-
Patent number: 11744809Abstract: An extended release tablet (ERT), having phentermine or a pharmaceutically acceptable salt thereof, and one or more of a wax and a pharmaceutically acceptable excipient selected from among one or more of a fatty acid, a bulking agent, a lubricant and the like is disclosed. A process for its preparation is also disclosed.Type: GrantFiled: November 7, 2017Date of Patent: September 5, 2023Assignee: ALPEX PHARMA SAInventors: Federico Stroppolo, Gabriele Granata
-
Patent number: 11730815Abstract: The invention is directed to stable liquid pharmaceutical compositions comprising, consisting of, or consisting essentially of bendamustine, at least one cyclodextrin, at least one non-aqueous solvent, at least about 2% water v/v of the composition, and at least one antioxidant, and their use for treating cancers, their preparation, and dosage forms containing them.Type: GrantFiled: May 20, 2020Date of Patent: August 22, 2023Assignee: GOOD HEALTH, LLCInventor: Basavaraj Siddalingappa
-
Patent number: 11731935Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.Type: GrantFiled: April 14, 2020Date of Patent: August 22, 2023Assignee: Praxis Bioresearch, LLCInventors: Sandeep Patil, Ron Bihovsky, Steven A Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
-
Patent number: 11723872Abstract: Provided is a rapid release tablet excellent in binding capability and disintegrability and also excellent in storage stability and the like. More specifically, provided are a granulated composite comprising low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of from 5 to 16% by weight and D-mannitol, wherein the D-mannitol contains 0.9% by weight or less of D-sorbitol; a rapid release tablet comprising the granulated composite and a drug; and a method for producing a granulated composite comprising the steps of: mixing low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of from 5 to 16% by weight, first D-mannitol, and water to obtain an aqueous dispersion, and granulating while adding the aqueous dispersion to second D-mannitol, wherein the first D-mannitol and the second D-mannitol contain 0.9% by weight or less of D-sorbitol in total.Type: GrantFiled: October 14, 2019Date of Patent: August 15, 2023Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Yasuyuki Hirama, Naosuke Maruyama
-
Patent number: 11685747Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: October 21, 2020Date of Patent: June 27, 2023Assignee: AMGEN INC.Inventor: Nick A. Paras
-
Patent number: 11684593Abstract: Applications of spermine or its pharmaceutically acceptable derivative in preparation of an SAICAR synthetase activity interfering agent or inhibitor. Applications of spermine or its pharmaceutically acceptable derivative in preparation of antitumor drug.Type: GrantFiled: February 6, 2018Date of Patent: June 27, 2023Assignee: Geneheal Biotechnology Co., Ltd.Inventors: Wei Zhu, Wuguang Pan
-
Patent number: 11672799Abstract: The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: January 28, 2019Date of Patent: June 13, 2023Assignee: NOVARTIS AGInventors: Atwood Kim Cheung, Natalie Dales, Timothy Brian Hurley
-
Patent number: 11648316Abstract: The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.Type: GrantFiled: October 10, 2018Date of Patent: May 16, 2023Assignee: ICURE BNP CO., LTD.Inventors: Jin Woo Park, Young Ro Byun, Young Kweon Choi, Kwan Young Chang, Jae Bum Lee